Compare SBFG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBFG | IPHA |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 141.7M |
| IPO Year | 2014 | N/A |
| Metric | SBFG | IPHA |
|---|---|---|
| Price | $21.67 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 5.8K | ★ 23.6K |
| Earning Date | 04-23-2026 | 03-26-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 27.33 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.10 | $1.18 |
| 52 Week High | $23.93 | $2.63 |
| Indicator | SBFG | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 46.46 |
| Support Level | $20.94 | $1.18 |
| Resistance Level | $22.70 | $1.80 |
| Average True Range (ATR) | 0.68 | 0.08 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 50.99 | 23.26 |
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.